Synlife

Co-founded by MIT scientists in 2017 and headquartered in Cambridge, MA, Synlife's team is developing therapeutic and diagnostic platforms through bottom-up engineering of synthetic cells. While much of synthetic biology relies on top-down engineering of extant living systems, this strategy is constrained by the fundamental drives of biology, such as evolutionary pressures and resource utilization for the necessary functions of life. By building synthetic minimal cells bottom-up, Synlife can reconstitute desirable functions of biology.